Informationen:
Fehler:
ID
19663
Beschreibung
A Study of Perjeta (Pertuzumab) in Combination With Herceptin in Patients With Metastatic Breast Cancer.; ODM derived from: https://clinicaltrials.gov/show/NCT01674062
Link
https://clinicaltrials.gov/show/NCT01674062
Stichworte
Versionen (2)
- 20.01.17 20.01.17 -
- 20.01.17 20.01.17 -
Hochgeladen am
20. Januar 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Breast Cancer NCT01674062
Eligibility Breast Cancer NCT01674062
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Breast Cancer NCT01674062
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Adult | Age | HER2-positive carcinoma of breast
Item
adult patients, >=18 years of age, with histologically-confirmed her2-positive breast cancer
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C1960398 (UMLS CUI [3])
C0001779 (UMLS CUI [2])
C1960398 (UMLS CUI [3])
Secondary malignant neoplasm of female breast | Disease Progression | Therapeutic procedure Herceptin Based Neoplasm Metastasis
Item
metastatic breast cancer, with progression on herceptin-based therapy as last treatment for metastatic disease
boolean
C0346993 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
C0087111 (UMLS CUI [3,1])
C0338204 (UMLS CUI [3,2])
C1705938 (UMLS CUI [3,3])
C0027627 (UMLS CUI [3,4])
C0242656 (UMLS CUI [2])
C0087111 (UMLS CUI [3,1])
C0338204 (UMLS CUI [3,2])
C1705938 (UMLS CUI [3,3])
C0027627 (UMLS CUI [3,4])
Chemotherapy Regimen Quantity
Item
<=3 chemotherapy regimens prior to study entry
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Herceptin Dose | pertuzumab
Item
last herceptin dose <=9 weeks before study entry for patients reciving pertuzumab +
boolean
C0338204 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1328025 (UMLS CUI [2])
C0178602 (UMLS CUI [1,2])
C1328025 (UMLS CUI [2])
Herceptin | pertuzumab
Item
herceptin, and >=4 weeks for patients receiving pertuzumab monotherapy
boolean
C0338204 (UMLS CUI [1])
C1328025 (UMLS CUI [2])
C1328025 (UMLS CUI [2])
Left ventricular ejection fraction
Item
lvef>= 55% at study entry
boolean
C0428772 (UMLS CUI [1])
Vaccines Against Malignant Neoplasms | Targeted Therapy | Herceptin
Item
previous treatment with an anti-cancer vaccine or any targeted therapy other than herceptin
boolean
C0042210 (UMLS CUI [1,1])
C0521124 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,3])
C2985566 (UMLS CUI [2])
C0338204 (UMLS CUI [3])
C0521124 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,3])
C2985566 (UMLS CUI [2])
C0338204 (UMLS CUI [3])
Metastatic malignant neoplasm to brain
Item
brain metastases
boolean
C0220650 (UMLS CUI [1])
Adverse event cardiac Herceptin Related
Item
history of any cardiac ae related to herceptin therapy
boolean
C0877248 (UMLS CUI [1,1])
C0018787 (UMLS CUI [1,2])
C0338204 (UMLS CUI [1,3])
C0439849 (UMLS CUI [1,4])
C0018787 (UMLS CUI [1,2])
C0338204 (UMLS CUI [1,3])
C0439849 (UMLS CUI [1,4])
Malignant Neoplasms | Basal cell carcinoma | Carcinoma in situ of uterine cervix
Item
any other malignancy in the last 5 years, except for basal cell cancer or cancer in situ of the cervix
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0851140 (UMLS CUI [3])
C0007117 (UMLS CUI [2])
C0851140 (UMLS CUI [3])